California-based clinical stage biotech company Phanes Therapeutics, Inc. (Phanes) announced on Friday that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its PT217, intended for the treatment of neuroendocrine carcinoma (NEC).
PT217, a first-in-class bispecific antibody, targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) and is being developed for patients with NEC. It received ODD for the treatment of small cell lung cancer (SCLC) from the FDA in 2022, and was granted Fast Track designation by the agency in 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
Earlier this year, Phanes signed a clinical supply agreement with Roche to study PT217 along with Roche's anti-PD-L1 therapy, atezolizumab.
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Sanofi and Regeneron's Dupixent approved for COPD in China
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi